New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

A new study published in the Journal of Neurosurgery highlights the potential of focused ultrasound technology in treating ...

With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Alzheimer’s is the most common form of dementia — it causes memory loss, confusion, thinking problems and behavioral changes.

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a novel -- and noble -- ...

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that ...

Researchers report hopeful progress in efforts to find treatments for Alzheimer’s disease. They report a recent clinical ...

A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

The search for answers to Alzheimer's disease and other neurodegenerative disorders remains one of the most pressing goals in brain research. Maciej J. Stawikowski, Ph.D., an assistant professor of ...

15, 2025 — Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid ... Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase ...